Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision: v3.5.2 was added and Revision: v3.5.0 was removed from the page.
    Difference
    0.1%
    Check dated 2026-04-16T10:55:22.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision text updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-18T15:45:26.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    - Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T10:00:22.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added, and the prior funding-status notice and Revision: v3.4.1 note were removed.
    Difference
    0.5%
    Check dated 2026-02-11T02:22:36.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    Added a government funding/status notice regarding the NIH Clinical Center. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.5%
    Check dated 2026-02-03T23:07:54.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    UI updates include adding a 'Show glossary' option, introducing a new label 'Last Update Submitted that Met QC Criteria,' updating the revision to v3.4.0, and capitalization tweaks for 'No FEAR Act Data'. These changes do not affect study content, eligibility criteria, or results.
    Difference
    0.2%
    Check dated 2026-01-27T20:31:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.